These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 28326014)

  • 1. The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome.
    Contestabile A; Magara S; Cancedda L
    Front Cell Neurosci; 2017; 11():54. PubMed ID: 28326014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations of specific cortical GABAergic circuits underlie abnormal network activity in a mouse model of Down syndrome.
    Zorrilla de San Martin J; Donato C; Peixoto J; Aguirre A; Choudhary V; De Stasi AM; Lourenço J; Potier MC; Bacci A
    Elife; 2020 Aug; 9():. PubMed ID: 32783810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome.
    Deidda G; Parrini M; Naskar S; Bozarth IF; Contestabile A; Cancedda L
    Nat Med; 2015 Apr; 21(4):318-26. PubMed ID: 25774849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GABAergic over-inhibition, a promising hypothesis for cognitive deficits in Down syndrome.
    Zorrilla de San Martin J; Delabar JM; Bacci A; Potier MC
    Free Radic Biol Med; 2018 Jan; 114():33-39. PubMed ID: 28993272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aerobic exercise and a BDNF-mimetic therapy rescue learning and memory in a mouse model of Down syndrome.
    Parrini M; Ghezzi D; Deidda G; Medrihan L; Castroflorio E; Alberti M; Baldelli P; Cancedda L; Contestabile A
    Sci Rep; 2017 Dec; 7(1):16825. PubMed ID: 29203796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroanatomical alterations and synaptic plasticity impairment in the perirhinal cortex of the Ts65Dn mouse model of Down syndrome.
    Roncacé V; Burattini C; Stagni F; Guidi S; Giacomini A; Emili M; Aicardi G; Bartesaghi R
    Neurobiol Dis; 2017 Oct; 106():89-100. PubMed ID: 28651891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mental retardation and associated neurological dysfunctions in Down syndrome: a consequence of dysregulation in critical chromosome 21 genes and associated molecular pathways.
    Rachidi M; Lopes C
    Eur J Paediatr Neurol; 2008 May; 12(3):168-82. PubMed ID: 17933568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced GIRK2 channel signaling in Down syndrome: A feasible role in the development of abnormal nascent neural circuits.
    Kleschevnikov AM
    Front Genet; 2022; 13():1006068. PubMed ID: 36171878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Communication breaks-Down: from neurodevelopment defects to cognitive disabilities in Down syndrome.
    Contestabile A; Benfenati F; Gasparini L
    Prog Neurobiol; 2010 May; 91(1):1-22. PubMed ID: 20097253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives.
    Stagni F; Bartesaghi R
    Front Cell Neurosci; 2022; 16():903729. PubMed ID: 35634470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.
    Gardiner KJ
    Drug Des Devel Ther; 2015; 9():103-25. PubMed ID: 25552901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological correction of excitation/inhibition imbalance in Down syndrome mouse models.
    Souchet B; Guedj F; Penke-Verdier Z; Daubigney F; Duchon A; Herault Y; Bizot JC; Janel N; Créau N; Delatour B; Delabar JM
    Front Behav Neurosci; 2015; 9():267. PubMed ID: 26539088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists.
    Kleschevnikov AM; Belichenko PV; Faizi M; Jacobs LF; Htun K; Shamloo M; Mobley WC
    J Neurosci; 2012 Jul; 32(27):9217-27. PubMed ID: 22764230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down syndrome: genes, model systems, and progress towards pharmacotherapies and clinical trials for cognitive deficits.
    Busciglio J; Capone G; O'Bryan J; Gardiner KJ
    Cytogenet Genome Res; 2013; 141(4):260-71. PubMed ID: 24008277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing GABAergic inhibition restores cognitive functions in a mouse model of Down syndrome.
    Potier MC; Braudeau J; Dauphinot L; Delatour B
    CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):8-15. PubMed ID: 24152333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating enhanced GABAergic inhibition in Down syndrome: use of GABA α5-selective inverse agonists.
    Martínez-Cué C; Delatour B; Potier MC
    Neurosci Biobehav Rev; 2014 Oct; 46 Pt 2():218-27. PubMed ID: 24412222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dyrk1a gene dosage in glutamatergic neurons has key effects in cognitive deficits observed in mouse models of MRD7 and Down syndrome.
    Brault V; Nguyen TL; Flores-Gutiérrez J; Iacono G; Birling MC; Lalanne V; Meziane H; Manousopoulou A; Pavlovic G; Lindner L; Selloum M; Sorg T; Yu E; Garbis SD; Hérault Y
    PLoS Genet; 2021 Sep; 17(9):e1009777. PubMed ID: 34587162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice.
    Braudeau J; Delatour B; Duchon A; Pereira PL; Dauphinot L; de Chaumont F; Olivo-Marin JC; Dodd RH; Hérault Y; Potier MC
    J Psychopharmacol; 2011 Aug; 25(8):1030-42. PubMed ID: 21693554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreasing the Expression of GABA
    Vidal V; García-Cerro S; Martínez P; Corrales A; Lantigua S; Vidal R; Rueda N; Ozmen L; Hernández MC; Martínez-Cué C
    Mol Neurobiol; 2018 Jun; 55(6):4745-4762. PubMed ID: 28717969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impairment of Sharp-Wave Ripples in a Murine Model of Dravet Syndrome.
    Cheah CS; Lundstrom BN; Catterall WA; Oakley JC
    J Neurosci; 2019 Nov; 39(46):9251-9260. PubMed ID: 31537705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.